71 West Capital Partners bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) in the 4th quarter, Holdings Channel.com reports. The institutional investor bought 936 shares of the company’s stock, valued at approximately $633,000.
Other institutional investors also recently modified their holdings of the company. Beacon Investment Advisory Services Inc. grew its position in shares of IDEXX Laboratories by 11.9% during the 4th quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock worth $42,588,000 after buying an additional 6,710 shares during the period. Nordea Investment Management AB grew its position in shares of IDEXX Laboratories by 114.1% during the 4th quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock worth $11,283,000 after buying an additional 8,845 shares during the period. NEOS Investment Management LLC grew its position in shares of IDEXX Laboratories by 82.7% during the 3rd quarter. NEOS Investment Management LLC now owns 30,051 shares of the company’s stock worth $19,199,000 after buying an additional 13,599 shares during the period. Procyon Advisors LLC acquired a new position in shares of IDEXX Laboratories during the 4th quarter worth about $1,966,000. Finally, Diversified Trust Co. grew its position in shares of IDEXX Laboratories by 223.5% during the 4th quarter. Diversified Trust Co. now owns 4,199 shares of the company’s stock worth $2,841,000 after buying an additional 2,901 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.
IDEXX Laboratories Trading Up 1.6%
NASDAQ:IDXX opened at $570.00 on Tuesday. IDEXX Laboratories, Inc. has a fifty-two week low of $506.91 and a fifty-two week high of $769.98. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The stock has a market capitalization of $44.96 billion, a PE ratio of 41.97, a price-to-earnings-growth ratio of 3.07 and a beta of 1.56. The business’s 50-day simple moving average is $563.07 and its 200-day simple moving average is $625.43.
Analysts Set New Price Targets
IDXX has been the subject of several analyst reports. Stifel Nicolaus decreased their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. UBS Group cut their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Citigroup began coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective on the stock. Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Seven investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $751.00.
Check Out Our Latest Stock Report on IDXX
IDEXX Laboratories Profile
IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.
IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.
Featured Articles
- Five stocks we like better than IDEXX Laboratories
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
